Floatz logo

Romidepsin

Immune System Diseases

Ivan S MoiseevSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

20 Active assets in the Immune System Diseases cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
Indapta Therapeutics, INC.
Phase 2BB
Fludarabine
Indapta Therapeutics, INC.
Phase 2BB
Monomethyl Fumarate
National Cancer Institute (NCI)
Phase 2BB
CYCLOSPORIN A
National Cancer Institute (NCI)
Phase 2BB
Ibrutinib
Oncternal Therapeutics, Inc
Phase 3B

View all 33 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →